Revenue
2024
2025
Allarity Therapeutics, Inc. (ALLR)
Price—Loading quote
Net income
2020
2021
2022
2023
2024
2025
Free cash flow
2020
2022
2023
2024
2025
Total cash / debt
CashTotal debt
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | |
|---|---|---|---|---|---|---|
| Revenue | $320,000 | $0 | — | — | — | — |
| Gross profit | — | — | — | −$2.3M | — | — |
| Research & development | $6.6M | $6.1M | $7.1M | $6.9M | $14.2M | $4.2M |
| Operating expenses | $12.9M | $27.2M | $17.1M | $34.5M | $26.6M | $8.3M |
| Operating income | −$12.6M | −$27.2M | −$17.1M | −$34.5M | −$26.6M | −$8.3M |
| EBITDAderived | — | −$27.2M | −$17.1M | −$34.4M | −$26.4M | −$8.3M |
| Net income | −$11.2M | −$24.5M | −$11.9M | −$16.1M | −$26.6M | −$6.6M |
| Basic EPSper diluted share | -$0.78 | -$15.65 | -$6,031.31 | -$3,093.42 | -$4.19 | -$2.03 |
| Diluted EPSper diluted share | — | — | -$10.26 | -$3,093.42 | -$4.19 | — |